Drug Development Archives

Blog

Why the Most Important Phase 3 Decisions Should Be Made Before Phase 3

Learn how advanced modeling for reimbursement strategy using MBMA and QSP strengthens payer evidence and…

CertaraMarch 24, 2026

Publication

Population Pharmacokinetic and Pharmacokinetic-Pharmacodynamic Analysis for Clazakizumab in Patients With End-Stage Kidney Disease Undergoing Dialysis

This study evaluated the pharmacokinetics (PK) and pharmacokinetic–pharmacodynamic (PK–PD) relationship of clazakizumab, an anti–interleukin-6 (IL-6)…

Danielle PillsburyMarch 24, 2026

Publication

Model-informed drug development to support nemolizumab clinical development in adults and adolescents with moderate to severe atopic dermatitis

This article describes how a model-informed drug development (MIDD) approach was used to support the…

CertaraMarch 24, 2026

Blog

Regulatory horizons 2026: clinical pharmacology strategy and regulatory expectations

Learn how regulatory expectations in clinical pharmacology are evolving and how to build a strategy…

CertaraMarch 24, 2026

Guide

Pediatric Drug Development and Pharmacometrics: Key Questions Sponsors Must Answer

Download Certara’s expert guide on pharmacometrics and pediatric drug development. Learn how modeling, MIDD, and…

CertaraMarch 19, 2026

Blog Knowledge Base

What is GLP (Good Laboratory Practice)?

Read this blog to understand GLP (Good Laboratory Practice) and associated QA audits, and proper…

CertaraMarch 18, 2026

Conference

Discovery & Development Europe 2026

CertaraMarch 13, 2026

Announcement

Certara Welcomes Arjun Bedi to its Board of Directors 

Certara has appointed Arjun Bedi to its Board of Directors. His life sciences expertise will…

CertaraMarch 12, 2026

Blog

Advancing pharmacoequity through model-informed drug development: Insights from ASCPT 2026

Explore how model-informed drug development and AI are advancing pharmacoequity and shaping the future of…

CertaraMarch 11, 2026

Announcement

Certara Announces 2026 Certainty Event

Certainty 2026: Explore AI-driven drug development and technological innovation at the leading biosimulation event for…

CertaraMarch 9, 2026

Drug Development

Why the Most Important Phase 3 Decisions Should Be Made Before Phase 3

Population Pharmacokinetic and Pharmacokinetic-Pharmacodynamic Analysis for Clazakizumab in Patients With End-Stage Kidney Disease Undergoing Dialysis

Model-informed drug development to support nemolizumab clinical development in adults and adolescents with moderate to severe atopic dermatitis

Regulatory horizons 2026: clinical pharmacology strategy and regulatory expectations

Pediatric Drug Development and Pharmacometrics: Key Questions Sponsors Must Answer

What is GLP (Good Laboratory Practice)?

Discovery & Development Europe 2026

Certara Welcomes Arjun Bedi to its Board of Directors

Advancing pharmacoequity through model-informed drug development: Insights from ASCPT 2026

Certara Announces 2026 Certainty Event

Newsletter sign up

Quick links

Solutions

Contact